NCT05286528View on ClinicalTrials.gov

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

CompletedOBSERVATIONAL
Enrollment

1,484

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Chronic Myeloid Leukaemia
Interventions
DRUG

Bosutinib

Bosutinib as prescribed in real world

DRUG

Imatinib

Imatinib as prescribed in real world

DRUG

Nilotinib

Nilotinib as prescribed in real world

DRUG

Dasatinib

Dasatinib as prescribed in real world

DRUG

Ponatinib

Ponatinib as prescribed in real world

Trial Locations (1)

Unknown

Pfizer, Budapest

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05286528 - Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | Biotech Hunter | Biotech Hunter